321 related articles for article (PubMed ID: 22129033)
1. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
2. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
[TBL] [Abstract][Full Text] [Related]
3. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
7. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
Nguyen W; Hodder AN; de Lezongard RB; Czabotar PE; Jarman KE; O'Neill MT; Thompson JK; Jousset Sabroux H; Cowman AF; Boddey JA; Sleebs BE
Eur J Med Chem; 2018 Jun; 154():182-198. PubMed ID: 29800827
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
11. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
12. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
16. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
17. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
18. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
19. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
20. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
[Next] [New Search]